08:00 , Mar 1, 2010 |  BC Week In Review  |  Company News

Alliance Pharma, Cambridge Laboratories deal

Specialty pharmaceutical company Alliance completed its previously announced acquisition of Cambridge Labs for up to £14.3 million ($22.1 million) in cash plus potential milestones of up to £2.1 million ($3.2 million) (see BioCentury, Feb. 15)....
08:00 , Feb 15, 2010 |  BC Week In Review  |  Company News

Alliance Pharma, Cambridge Laboratories deal

Specialty pharmaceutical company Alliance will acquire Cambridge Labs for up to £14.3 million ($22.3 million) in cash plus potential milestones of up to £2.1 million ($3.3 million). Alliance gains 18 marketed prescription drugs in the...
08:00 , Feb 15, 2010 |  BioCentury  |  Finance

Regulatory milestones

Cadence Pharmaceuticals Inc. (NASDAQ:CADX) lost $1.16 (11%) to $9.34 last week after FDA issued a complete response letter for an NDA for Ofirmev IV acetaminophen to manage pain and reduce fever (see B9). Cell Therapeutics...
01:48 , Feb 9, 2010 |  BC Extra  |  Company News

Alliance Pharma to acquire Cambridge Labs

Specialty pharmaceutical company Alliance Pharma plc (LSE:APH) plans to acquire Cambridge Laboratories Ltd. (Dublin, Ireland) for up to L14.3 million ($22.3 million) in cash plus potential milestones of up to L2.1 million ($3.3 million). Alliance...
07:00 , Sep 17, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Calmodulin; huntingtin (HTT) Studies in mice suggest that disrupting the interaction between calmodulin and HTT could be useful for treating HD....
07:00 , Jul 13, 2009 |  BC Week In Review  |  Company News

LifeHealth, NeuronIcon, Lundbeck deal

H. Lundbeck acquired LifeHealth for $147 million in cash. The pharma said the deal will reduce the royalties paid to third parties on Xenazine tetrabenazine to 40-47% from 65-72%. LifeHealth has a 25% share of...
07:00 , Jun 29, 2009 |  BC Week In Review  |  Company News

Biovail, Cambridge Laboratories sales and marketing update

Biovail completed its previously announced acquisition of a portfolio of tetrabenazine products from Cambridge for $200 million up front, plus $30 million in two tranches over two years (see BioCentury, May 25). Biovail Corp. (TSX:BVF;...
07:00 , May 25, 2009 |  BC Week In Review  |  Company News

Biovail, Cambridge Laboratories, GlaxoSmithKline sales and marketing update

Biovail will acquire worldwide rights to a portfolio of tetrabenazine products from Cambridge for $200 million up front, plus $30 million in two tranches over two years. The deal includes Xenazine / Nitoman tetrabenazine, tetrabenazine...
07:00 , May 25, 2009 |  BioCentury  |  Finance

Ebb & Flow

In just six years, Cougar Biotechnology Inc. (NASDAQ:CGRB) has managed to turn a Phase I prostate cancer candidate, a reverse merger and $138 million into a $1 billion acquisition by Johnson & Johnson (NYSE:JNJ). The...
01:13 , May 19, 2009 |  BC Extra  |  Company News

Biovail acquiring tetrabenazine portfolio

Biovail Corp. (TSX:BVF; NYSE:BVF) will acquire worldwide rights to a portfolio of tetrabenazine products from Cambridge Laboratories Ltd. (Dublin, Ireland) for $200 million up front, plus $30 million in two tranches over two years. The...